Health
STEP 2 shows benefits of higher semaglutide dose in type 2 diabetes – medwireNews
The STEP 2 trial shows that overweight or obese people with type 2 diabetes achieve greater weight loss and larger improvements in cardiometabolic risk factors…
medwireNews: The STEP 2 trial shows that overweight or obese people with type 2 diabetes achieve greater weight loss and larger improvements in cardiometabolic risk factors when given a higher semaglutide dose than is currently approved.
Improvements in glycemic control were relatively small, with glycated hemoglobin (HbA1c) levels falling by an average of 1.6% (17.5 mmol/mol) among people randomly assigned to receive weekly semaglutide 2.4 mg for 68 weeks and 1.5% (15.9 mmol/mol) among those given…
-
Noosa News23 hours agoMeet Chad Burgess, Pauline Hanson’s One Nation Party
-
General22 hours agoTyler Wright soaks up Bells Beach return as poor conditions at Rip Curl Pro sees men’s opening round called off
-
Noosa News24 hours agoWestern Queensland graziers begin grim stock count after catastrophic floods
-
General22 hours agoTruck driver charged with causing death by dangerous driving after highway crash